For yet another year, Pharmathen has been distinguished at the “2018 EU Industrial R&D Investment Scoreboard” and is ranked first among Greek companies based on R&D spending, by investing 33% of its turnover. With annual R&D spending of 49.9 million euros in the 2017-2018 period, Pharmathen ranked 396th on this year’s list of 1,000 companies in the EU with the highest R&D expenditure.
Furthermore, based on the number of patent filings, Pharmathen is placed among the 3 companies to have filed and received the 29% of patents during the 2013-2015 period, in our country.
For the original “2018 EU Industrial R&D Investment Scoreboard” announcement please click on the following link:
The Economics of Industrial Research & Innovation (IRI) is a scientific project carried out within the Directorate B: Growth and Innovation of the European Commission's Joint Research Centre (JRC).